Marshall Wace North America’s Aratana Therapeutics, Inc. PETX Stock Holding History

Marshall Wace North America’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-16,223	Closed	-$99K	–	2082
2018 Q4	$99K	Buy	+16,223	New	+$99K	﹤0.01%	1086
2018 Q3	–	Sell	-61,677	Closed	-$262K	–	1592
2018 Q2	$262K	Sell	61,677 -96,853	-61%	-$488K	﹤0.01%	1213
2018 Q1	$699K	Buy	+158,530	New	+$707K	﹤0.01%	1085

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Marshall Wace North America's PETX Position: Q1 2019 in Review

Marshall Wace North America sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 16,223 shares — an estimated $99K sold.

Marshall Wace North America first reported a position in PETX in Q1 2018 and held it in 3 quarters. The position peaked at $699K in Q1 2018. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

Marshall Wace North America reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Marshall Wace North America sold 16,223 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $99K.
Marshall Wace North America first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
Marshall Wace North America's Aratana Therapeutics, Inc. position peaked at $699K in Q1 2018.
104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.